Tranexamic Acid During Colonic Endoscopic Resection Procedures
Recruiting · NCT05345613 · Interventional (participants receive a specific treatment) · Lead sponsor: Assaf-Harofeh Medical Center
View the official record on ClinicalTrials.gov →Interventions studied
What this trial is about
Colonoscopy with polypectomy reduces the incidence and mortality associated with colon cancer. However, polypectomy is associated with adverse events such as bleeding. Tranexamic acid (TXA) is a synthetic derivative of lysine that exerts antifibrinolytic effects and may prevent bleeding. The investigators aim to evaluate the effect of local TXA on preventing intraprocedural and postprocedural bleeding in patients undergoing endoscopic mucosal resection (EMR) of large colon polyps.
Who can take part
Age range
18 Years and older
Sex
All (male and female)
Healthy volunteers
No - a diagnosis or condition is required
Phase
Phase 4
Study type
Interventional (participants receive a specific treatment)
Inclusion criteria
- Patients referred for endoscopic resection of non-neoplastic and neoplastic lesions in the colon presenting to our tertiary academic center.
- Age \> 18 years
Exclusion criteria
- patients with histories of allergic reactions to TXA
- history of seizures
- pregnancy
Where it is running
1 location listed.
- Shamir Medical Center - Be’er Ya‘aqov, Israel